ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

By sjmartinez • August 31, 2023

Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, Wohl DA, Daar ES, Hughes MD; ACTIV-2/A5401 Study Team. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. J Infect Dis. 2023 Aug 31;228(Supplement_2):S77-S82. doi: 10.1093/infdis/jiad246. PMID: 37650231; PMCID: PMC10469341.

Tags: ACTIV-2, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, Publications

When Is Enough Enough? Additional Evidence of the Power of Zero

Budoff MJ. When Is Enough Enough? Additional Evidence of the Power of Zero. Circ Cardiovasc Imaging. 2024 Dec 20:e017714. doi: 10.1161/CIRCIMAGING.124.017714. Epub ahead of print.[...]

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”

Punnanithinont N, Kambalapalli S, Iskander B, Ichikawa K, Krishnan S, Lakshmanan S, Roy SK, Budoff M. "Anti-inflammatory Therapies in Atherosclerosis - Where are we going?".[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]